MedPage Today on MSN

In-Utero Repair of Severe Spina Bifida With Stem Cells Shows Promise

A first in-human, phase I trial examined feasibility as well as safety ...
Yahoo Finance

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market ...

New FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients Lens-based vision correction ...

Chicago Fire, Med and PD Reckoning crossover recap: Lives hang in the balance

Chicago Fire, Med and PD come together for the 2026 One Chicago crossover, a three-part event that rocks the One Chicago ...
ascopubs.org

Emerging oncology drug targets in the 21st century: An FDA analysis.

Prioritizing targeted therapies in an evidence-based manner, integrating biological context and functional precision medicine. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I.